April 4, 2014, Hollywood, FL. Outcome Capital announced today that it acted as the exclusive agent on a private placement of growth financing in Pure Life Renal, a dialysis management company. The capital was provided by Montreux Equity Partners and Noro-Moseley Partners.
About Pure Life Renal
Pure Life Renal is an independent provider of dialysis services and renal care providing a full spectrum of renal services including in-center, home-based and acute dialysis, as well as drug provisions. The Company plans a rapid expansion hybrid strategy through acquisitions and de novo development opportunities across the US. The Company was founded and is managed by a highly experienced executive team with an established track record of multiple exits in the dialysis sector through organic growth as well as through leveraging acquisition opportunities. The Company will also partner with nephrologists who are eager to grow their practice and who can demonstrate an established patient base and quality care. PureLife Renal is headquartered in Hollywood, FL. Please visit www.plrenal.com to learn more.
About Montreux Equity Partners
Montreux Equity Partners is a private investment firm dedicated to building the leading healthcare companies of tomorrow. Their portfolio companies meet the most compelling domestic and global healthcare needs. They are currently investing out of their fifth fund. Montreux is based in San Francisco, CA. Please visit www.mepvc.com to learn more.
About Noro-Moseley Partners
Noro-Moseley is a private equity and venture capital firm focusing on high-growth companies in the information technology and healthcare industries. Their primary focus is on companies that have achieved a level of customer acceptance that is evidenced by on-going revenue. Noro-Moseley is headquartered in Atlanta, GA. Please visit www.noromoseley.com to learn more.
BOSTON–(BUSINESS WIRE)–Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that ELIOS Vision, Inc. completed a growth financing round to support its European commercialization. Outcome Capital served as the exclusive strategic and financial advisor to the company. ELIOS’ implant-free, minimally invasive Excimer Laser Trabeculostomy glaucoma procedure is approved […]Read More
Outcome Capital Life Science Market Pulse July 2022 Click to view our LifeSciences Pulse NewsletterDownload